Rib-X Pharma files for IPO to finance antibiotics providing superior coverage
This article was originally published in Scrip
Executive Summary
Infectious disease company Rib-X Pharmaceuticals of New Haven, Connecticut, which has been operating since 2000, has decided to take a shot and go public. Even though it has not said how many shares it plans to sell in its initial public offering, it said in the proposed IPO that it seeks to raise as much as $80 million, according to a filing with the US Securities and Exchange Commission.